http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101624344-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 |
| filingDate | 2014-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101624344-B1 |
| titleOfInvention | Novel 3-Substituted-2-Oxoindoline-Based N-hydroxypropenamides Having Activity of Inhibiting Histone Deacetylase and Antitumor Composition Comprising the Same |
| abstract | The present invention relates to novel 3-hydroxyimino-2-oxoindoline-based N-hydroxypropeneamide compounds or 3-methoxyimino-2-oxoindoline-based N-hydroxypropeneamide compounds and their use as active ingredients As an anticancer agent. The hydroxamic acid compound of the present invention has a strong histone deacetylase (HDAC) inhibitory activity and exhibits proliferation inhibitory activity against various cancer cells. The compounds of the present invention can be developed as active ingredients of potent anti-cancer agents. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107011238-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107011238-B |
| priorityDate | 2014-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 252.